Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014 | Zendy

Hélio S. Sader | Zendy; Mariana Castanheira | Zendy; Robert K. Flamm | Zendy; Ronald N. Jones | Zendy

Open Access

Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014

Author(s) -

Hélio S. Sader,

Mariana Castanheira,

Robert K. Flamm,

Ronald N. Jones

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00405-16

Subject(s) - ceftazidime/avibactam , antimicrobial , ceftazidime , microbiology and biotechnology , medicine , urinary system , gram , gram negative bacteria , anti infective agents , gram negative bacterial infections , antibiotics , pseudomonas aeruginosa , intensive care medicine , biology , bacteria , escherichia coli , genetics , biochemistry , gene

A total of 7,272 unique patient clinical isolates were collected from 71 U.S. medical centers from patients with urinary tract infections in 2012 to 2014 and tested for susceptibility to ceftazidime-avibactam and comparators by broth microdilution methods. Ceftazidime-avibactam inhibited >99.9% of allEnterobacteriaceae at the susceptible breakpoint of ≤8 μg/ml (there were only three nonsusceptible strains). Ceftazidime-avibactam was also active againstPseudomonas aeruginosa isolates (MIC50 , 2 μg/ml; MIC90 , 4 μg/ml; 97.7% susceptible), including many isolates not susceptible to meropenem, ceftazidime, and/or piperacillin-tazobactam.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research